Assembly Biosciences, Inc. (ASMB) stock
Close on Nov 12, 2026Market cap $410.88MP/E –Yield –
Assembly Biosciences, Inc. grew revenue 80.2% to $67.01M over the twelve months to Sep 30, 2026. Free cash flow was -$40.68M. At the latest close the market valued the company at $410.88M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $410.88M
- P/E ratio
- –
- Price to sales
- 6.13
- Price to book
- 1.38
- Dividend yield
- –
- Free cash flow yield
- -9.90%
Fundamentals
- Revenue
- $67.01M
- Net income
- -$11.10M
- EPS, diluted
- -$0.55
- Free cash flow
- -$40.68M
- Book value per share
- $13.72
- Diluted shares
- 22M
Trading
- Next earnings
- Q3 FY2026, expected soon
- Previous close
- $22.37
- Open
- $22.10
- Day's range
- $19.84 – $22.15
- Volume
- 499,584
- Average volume (20 days)
- 236,715
- Index membership
- Russell 2000 (since Jun 2026)
- Beta (5 years)
- 1.18
- 52-week range
- $19.20 – $39.70
- RSI (14 days)
- 55.6
- Volatility (1 year)
- 59.2%
- Relative volume
- 0.78×
- WACC
- 10.8%
On 2 of our idea lists: More cash than they're worth, Institutions accumulating
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | ASMB | S&P 500 | Difference | ASMB per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -11.4% | -2.7% | −8.7 pts | ||
| 3 months | -25.4% | -1.7% | −23.7 pts | ||
| Year to date | -40.7% | +11.9% | −52.6 pts | ||
| 1 year | -43.7% | +12.0% | −55.7 pts | ||
| 3 years | +124.2% | +78.2% | +46.0 pts | +30.9% | +21.2% |
| 5 years | -42.0% | +73.2% | −115.3 pts | -10.3% | +11.6% |
| 10 years | -87.1% | +309.6% | −396.7 pts | -18.5% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Assembly Biosciences filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- News
- Update
- Results
- Results
About Assembly Biosciences
Pharmaceutical Preparations
The company is a clinical-stage biotechnology enterprise that develops novel therapeutic candidates targeting serious viral infections. Its pipeline comprises multiple investigational treatments, including helicase-primase inhibitors for recurrent genital herpes, an oral entry inhibitor for hepatitis delta virus, and a next-generation capsid assembly modulator for chronic hepatitis B. The company also develops an oral broad-spectrum non-nucleoside polymerase inhibitor for transplant-associated herpesviruses. Its target end users are patients suffering from severe, chronic, or recurrent viral illnesses, including immunocompromised individuals undergoing organ transplants.
Company profile, executives and historyAssembly Biosciences stock: common questions
What is Assembly Biosciences's stock price?
ASMB closed at $20.18 on Nov 12, 2026, down 9.79% on the day. Over the past 52 weeks it traded between $19.20 and $39.70.
What is Assembly Biosciences's market cap?
Assembly Biosciences was worth $410.88M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is ASMB's P/E ratio?
Assembly Biosciences lost money over fiscal 2025 (diluted EPS -$0.55), so it has no meaningful P/E ratio.
How much revenue does Assembly Biosciences make?
Assembly Biosciences reported revenue of $67.01M for the twelve months to Sep 30, 2026, up 80.2% from a year earlier.
Does Assembly Biosciences pay a dividend?
No. Assembly Biosciences has not paid a cash dividend over the last twelve months.
When does Assembly Biosciences report earnings next?
Assembly Biosciences's Q3 FY2026 results are due soon; the company has not yet filed them with the SEC.
How has ASMB stock performed over the past year?
Including dividends, ASMB returned -43.7% over the past year, against +12.0% for the S&P 500.
How many ASMB shares are sold short?
3M shares were sold short at the latest FINRA report, 21.07% of the float, or 17.0 days of average trading volume.
Who are Assembly Biosciences's competitors?
Companies most similar to Assembly Biosciences by business, industry and size include ENTA, WVE, AMLX, BCYC, GOSS.
See a number that looks wrong?